Single-Use Systems Expand in CGT
Single-use technologies are gaining momentum in cell and gene therapy manufacturing due to their flexibility and reduced risk of cross-contamination. These systems are particularly suited for the small-batch, high-mix production common in viral vector development, with a growing industry focus on integrating digital sensors and analytics into these platforms.
- The implementation of digital twins in viral vector manufacturing, which combines mechanistic models with process analytical technology (PAT), has been shown to increase productivity by 20% while ensuring 99.9% reliability. These digital replicas of the bioprocess allow for virtual experiments to optimize parameters and de-risk scale-up before implementation. - A significant challenge in CGT data management is the lack of standardized assays and data management tools, which leads to inefficiencies. Integrating disparate systems like LIMS, MES, and ERP is a major hurdle in implementing electronic batch records (EBRs), often requiring custom development to handle incompatible data formats. - The cell and gene therapy CDMO market is experiencing an imbalance, with manufacturing capacity growth outpacing the growth of active clinical trials by more than two-to-one between 2019 and 2024. Despite this, the global CGT CDMO market is projected to grow from $8.07 billion in 2025 to approximately $74.03 billion by 2034. - Automation is a key trend in addressing manufacturing bottlenecks, with a shift from manual, open processes to automated, closed systems to reduce contamination risks and improve reproducibility. Automated platforms for cell line development, such as CYTENA's C.STATION, are designed to accelerate workflows while enhancing quality. - AI and machine learning are being increasingly applied to optimize bioprocesses by analyzing large datasets to predict optimal operating conditions, improve yields, and ensure consistent product quality. These technologies, combined with real-time sensor data, can preemptively identify process deviations and trigger corrective actions, significantly reducing batch failures. - The biotech funding climate has become more challenging, with venture capital for cell and gene therapy falling from a peak of $8.2 billion in 2021. Investors are now more cautious, favoring companies with clinically validated pipelines and creating a difficult fundraising environment for many startups. - Electronic batch record (EBR) systems are critical for managing the process variability and intensive documentation requirements inherent in gene therapy manufacturing. However, implementation faces challenges including employee resistance to change, the high cost of implementation, and the complexity of integrating with existing systems like LIMS and ERP. - There is a strategic shift from adherent to suspension cell cultures for viral vector production to improve scalability and reduce batch-to-batch variability, aligning processes more closely with established monoclonal antibody production methods. Additionally, fixed-bed bioreactors are being implemented for adherent cultures as a closed, automated alternative to traditional manual platforms.
